Fernanda Pilatti da Silva

Fernanda Pilatti da Silva

Auto-generated profile, based on publicly available information

Fernanda Pilatti da Silva

Postgraduate Program in Pharmaceutical Sciences, Palafito, Universidade Estadual de Maringá, Maringá, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Revista Brasileira de Farmacognosia
Verified
Journal Article
Closed access
PDF file
Mariana Nascimento de PaulaMariana Nascimento de Paula
Mariana Nascimento de Paula
MKMaren Kelm
Maren Kelm
NSNico Symma
Nico Symma
RIRaquel Isolani
Raquel Isolani
FSFernanda Pilatti da Silva
Fernanda Pilatti da Silva
JMJoão Carlos Palazzo de Mello
João Carlos Palazzo de Mello

22 May 2022 in Planta Medica
Verified
Journal Article
Closed access
PDF file
FPFernanda Pilatti
Fernanda Pilatti
RIRaquel Isolani
Raquel Isolani
LVLarissa Valone
Larissa Valone
Mariana Nascimento de PaulaMariana Nascimento de Paula
Mariana Nascimento de Paula
ACAngelo de Oliveira Caleare
Angelo de Oliveira Caleare
JMJoão Carlos Palazzo de Mello
João Carlos Palazzo de Mello
Periodontal diseases are a global oral health problem affecting almost 10% of the global population. Porphyromonas gingivalis is one of the main bacteria involved in the initiation and progression of inflammatory processes as a result of the action of the cysteine proteases lysin- and arginine-gingipain. Surelease/polycarbophil microparticles containing a lyophilized proanthocyanidin-enriched fraction from the rhizomes of Limonium brasiliense, traditionally named “baicuru” (ethyl acetate fraction), were manufactured. The ethyl acetate fraction was characterized by UHPLC by the presence of samarangenins A and B (12.10 ± 0.07 and 21.05 ± 0.44%, respectively) and epigallocatechin-3-O-gallate (13.44 ± 0.27%). Physiochemical aspects of Surelease/polycarbophil microparticles were characterized concerning particle size, zeta potential, entrapment efficiency, ethyl acetate fraction release, and mucoadhesion. Additionally, the presence of the ethyl acetate fraction-loaded microparticles was performed concerning potential influence on viability of human buccal KB cells, P. gingivalis adhesion to KB cells, gingipain activity, and P. gingivalis biofilm formation. In general, all Surelease/polycarbophil microparticles tested showed strong adhesion to porcine cheek mucosa (93.1 ± 4.2% in a 30-min test), associated with a prolonged release of the ethyl acetate fraction (up to 16.5 ± 0.8% in 24 h). Preincubation of KB cells with Surelease/polycarbophil microparticles (25 µg/mL) resulted in an up to 93 ± 2% reduced infection rate by P. gingivalis. Decreased activity of the P. gingivalis-specific virulence factors lysin- and arginine-gingipain proteases by Surelease/polycarbophil microparticles was confirmed. Surelease/polycarbophil microparticles decreased biofilm formation of P. gingivalis (97 ± 2% at 60 µg/mL). Results from this study prove the promising activity of Surelease/polycarbophil microparticles containing ethyl acetate fraction microparticles as a prophylaxis strategy to prevent the recurrence of P. gingivalis.